Jimmy Ruiz, MD | Wake Forest University ...

Dr. Jimmy Ruiz

Claim this profile

Wake Forest University Health Sciences

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
24 drugs studied

Area of expertise

1Lung Cancer
Jimmy Ruiz has run 8 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Jimmy Ruiz has run 6 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive

Affiliated Hospitals

Image of trial facility.
Wake Forest University Health Sciences
Image of trial facility.
Wake Forest University At Clemmons

Clinical Trials Jimmy Ruiz is currently running

Image of trial facility.

Tazemetostat + Topotecan + Pembrolizumab

for Small Cell Lung Cancer

This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.
Recruiting1 award Phase 119 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Jimmy Ruiz

Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Jimmy Ruiz has experience with
  • Pembrolizumab
  • Carboplatin
  • Berzosertib
  • Gemcitabine Hydrochloride
  • Topotecan Hydrochloride
  • Zimberelimab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jimmy Ruiz specialize in?
Is Jimmy Ruiz currently recruiting for clinical trials?
Are there any treatments that Jimmy Ruiz has studied deeply?
What is the best way to schedule an appointment with Jimmy Ruiz?
What is the office address of Jimmy Ruiz?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security